Skip to main content
FDA Approves Adagrasib for KRAS G12C–Mutated CRC
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
FDA Approves Adagrasib for KRAS G12C–Mutated CRC
User login
Username
Password
Reset your password
Concept
Lead
score
Colorectal Cancer
1
1
Biologic Therapy
0
0.99
KRAS
0
0.98
Otolaryngology
0
0.81
Lung Cancer
0
0.56
Small Cell Lung Cancer
0
0.54
Toxicology
0
0.53
Acute Pain
0
0.51
Pain Management
0
0.37
Cancer
0
0.28
Monoclonal Antibody
0
0.28
Cancer Pain
0
0.24
Abdominal Pain
0
0.16
Constipation
0
0.14
Diarrhea
0
0.14
Grant
0
0.14
Headache
0
0.14
Pain
0
0.14
Peripheral Neuropathy
0
0.1
VEGF Inhibitor
0
0.1
Abdomen
0
0.07
Anemia
0
0.07
Chemotherapy
0
0.07
Cough
0
0.07
Dizziness
0
0.07
Edema
0
0.07
Face
0
0.07
Fatigue
0
0.07
Food and Drug Administration (FDA)
0
0.07
Lung
0
0.07
Nausea
0
0.07
Neuropathy
0
0.07
Prognosis
0
0.07
Texas
0
0.07
Vascular Endothelial Growth Factor
0
0.07
Xeroderma
0
0.07
Specialty
Lead
score
Hematology-Oncology
1
1
Gastroenterology
0
0.8
Pharmacist
0
0.7
Pulmonary Medicine
0
0.9
Edit Tags